Welcome back to the Oncology Brothers podcast! In this episode, we continue the three-part CME series on small cell lung cancer, focusing on adverse events and management strategies for extensive stage small cell lung cancer treatments.

We are thrilled to have Dr. Misty Shields from the Indiana University join us to discuss the latest advancements in treatment options following the exciting data presented at ASCO 2025. We dived into the treatment algorithm for patients with good performance status, including the use of chemoimmunotherapy, lurbinectedin, and tarlatamab.

Key topics covered in this episode:

Join us as we explore the challenges and opportunities in managing extensive stage small cell lung cancer, and learn how to provide the best care for patients facing this devastating disease.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

Link to gain CME credits from this activity:

Follow us on social media:

#SCLCtoxicity #Lurbinectedin #Tarlatamab #SupportiveOncology #CMEoncology

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rohit & Rahul Gosain are joined by Dr. Joshua Sabari from the NYU Langone Cancer Center to discuss the exciting recent approval of Zongertinib, the first oral TKI for HER2-positive lung cancer.

We dived deep into the prevalence of HER2 mutations in non-small cell lung cancer, the study design and findings from the Beamion LUNG-1 trial, and the implications of this new therapy in clinical practice. Dr. Sabari shared insights on the efficacy of Zongertinib, including impressive response rates and progression-free survival data, as well as its side effect profile compared to other treatments like trastuzumab deruxtecan (T-DXd).

Key topics covered in this episode:

Join us for this informative discussion as we explore the latest advancements in lung cancer treatment and what they mean for patients and clinicians alike. Don't forget to subscribe for more episodes on new approvals, side effect management, and practice-changing data in oncology!

Follow us on social media:

Welcome to the Oncology Brothers podcast! In this episode, we kick off a three-part CME series focused on small cell lung cancer (SCLC). Joined by Dr. Hossein Borghaei, Chief of Thoracic Oncology at the Fox Chase Cancer Center. Together they dived into the evolving treatment landscape for SCLC, highlighting recent advancements and data from ASCO 2025.

Episode Highlights:

Join us as we navigate the complexities of SCLC treatment and look forward to future advancements that may improve patient outcomes.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

Link to gain CME credits from this activity:

Follow us on social media:

#OncologyBrothers #SmallCellLungCancer #CME #ASCO2025 #LungCancer #Immunotherapy #CancerTreatment

In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC).

Key Topics:

Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations. 

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!

Welcome to the Oncology Brothers podcast! In this episode, we continue our hematology series by diving deep into myelofibrosis (MF) with Dr. Raajit Rampal, an expert in myeloproliferative neoplasms from the Memorial Sloan Kettering Cancer Center.

Join Drs. Rahul and Rohit Gosain as they discuss the latest updates in symptom management, emerging treatment combinations, and the importance of timely diagnosis and risk stratification for patients presenting with cytopenias and splenomegaly.

Key topics covered in this episode include:

Tune in to gain valuable insights into the evolving treatment landscape for myelofibrosis and learn how community oncologists can effectively manage this complex disease.

Follow us on social media:

Don't forget to subscribe for more episodes in our hematology series and check out our previous discussions!

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC).

Episode Highlights:

Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC. 

Follow us on social media:

Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dived deep into the world of myeloproliferative neoplasms (MPNs), focusing specifically on polycythemia vera (PV) and essential thrombocythemia (ET). They are joined by Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, who shared his expertise on the latest treatment paradigms and risk stratification strategies for these conditions.

Key topics discussed included:

Join us for an informative discussion that highlights the evolving landscape of MPN management and the importance of individualized treatment plans. 

Follow us on social media:

Don't forget to check out our other hematology episodes for more insights into challenging cases and treatment algorithms!

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain, practicing community oncologists, share their key takeaways from a session on NTRK Fusion Positive Solid Malignancies, they moderated during a satellite event at ASCO 2025 in partnership with Medscape Global Oncology.

Join us as we discuss:

Don't forget to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit. 

https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679 

Follow us on social media:

#entrectinib #larotrectinib #repotrectinib

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the complexities of relapsed refractory Acute Myeloid Leukemia (AML) with FLT3 mutations. Joined by leukemia specialists Dr. Uma Borate from the Ohio State University and Dr. Naval Daver from the MD Anderson Cancer Center, the discussion focused on real-life cases and the current standard of care for patients with FLT3-positive AML.

Key topics included:

Whether you're a healthcare professional or someone interested in the latest advancements in cancer care, this episode provides valuable insights into the management of challenging AML cases.

Follow us on social media:

Don't forget to subscribe for more discussions on the latest in oncology!

In this episode of The Oncology Brothers, Drs. Rahul and Rohit Gosain are joined by Dr. Anand Patel, a hematologist and Medical Director of Inpatient Leukemia Service at the University of Chicago. Together, they delved into the complexities of acute myeloid leukemia (AML), one of the most aggressive cancers encountered in clinical practice.

Episode Highlights:

Follow us on social media:

YouTube: https://youtu.be/gbgRbrjHxmQ

Join us as we bridge the gap between academic research and community practice, providing valuable insights for healthcare professionals treating AML patients. 

Don't forget to like, subscribe, and check out our other episodes for more discussions on challenging cases and treatment algorithms!